Evaluation of once-daily dosing and target concentrations in therapeutic drug monitoring for arbekacin: A meta-analysis

Matsumoto, 2014, Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens, Clin Pharmacol, 6, 139 Kurebe, 1986, Antibacterial activity and ototoxicity in Guinea pigs, and nephrotoxicity in rats of arbekacin, Arzneimittelforschung, 36, 1511 Jackson, 2018, Discovery and development of new antibacterial drugs: learning from experience?, J Antimicrob Chemother, 73, 1452, 10.1093/jac/dky019 Serio, 2018, Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation, EcoSal Plus, 8, 10.1128/ecosalplus.ESP-0002-2018 Nakamura, 2015, New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa, Eur J Clin Microbiol Infect Dis, 34, 83, 10.1007/s10096-014-2192-x Okada, 2014, Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring, J Infect Chemother, 20, 1, 10.1016/j.jiac.2013.08.008 Sato, 2006, Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 50, 3763, 10.1128/AAC.00480-05 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, 10.1371/journal.pmed.1000097 Sterne, 2016, ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions, BMJ, 355, i4919, 10.1136/bmj.i4919 Kimura, 2012, Clinical investigation of arbekacin sulfate based on Cmax/MIC, Jpn J Antibiot, 65, 263 Miura, 2016, Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies, Int J Hematol, 103, 334, 10.1007/s12185-015-1926-6 Matsumoto, 2013, Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study, J Infect Chemother, 19, 128, 10.1007/s10156-012-0519-z Kimura, 2011, Dose finding study on arbekacin sulfate for appropriate peak levels, Jpn J Chemother, 59, 597 Tanikaze, 2004, Study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection, Jpn J Chemother, 52, 469 Kawano, 2010, Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring, Jpn J Ther Drug Monitor, 27, 55 Aikawa, 2008, An open clinical study of arbekacin 200 mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) -A clinical pharmacology study-, Jpn J Chemother, 56, 299 Yamamoto, 2012, The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection, J Infect Chemother, 18, 241, 10.1007/s10156-012-0397-4 Kobayashi, 2006, Pharmacokinetic and pharmacodynamic (PK/PD) analysis to determine the optimal method of arbekacin administration, Jpn J Chemother, 54, 18 Nagai, 2004, Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity, Drug Metabol Pharmacokinet, 19, 159, 10.2133/dmpk.19.159 Williams, 1987, Correlation between renal membrane binding and nephrotoxicity of aminoglycosides, Antimicrob Agents Chemother, 31, 570, 10.1128/AAC.31.4.570 Blaser, 1995, Once-daily dosing of aminoglycosides, Eur J Clin Microbiol Infect Dis, 14, 1029, 10.1007/BF01590935 Barza, 1996, Single or multiple daily doses of aminoglycosides: a meta-analysis, BMJ, 312, 338, 10.1136/bmj.312.7027.338 Munckhof, 1996, meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses, J Antimicrob Chemother, 37, 645, 10.1093/jac/37.4.645 Hatala, 1996, Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis, Ann Intern Med, 124, 717, 10.7326/0003-4819-124-8-199604150-00003 Smyth, 2017, Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis, Cochrane Database Syst Rev, 3, CD002009 Mavros, 2011, Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis, J Antimicrob Chemother, 66, 251, 10.1093/jac/dkq451 Bastone, 1993, Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing, Antimicrob Agents Chemother, 37, 914, 10.1128/AAC.37.4.914 Aoki, 1994, Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureus, Jpn J Antibiot, 47, 640 2012, KDIGO clinical practice guideline for acute kidney injury, Kidney Int, Suppl 2, 1 Vincent, 1996, The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working Group on sepsis-related problems of the European society of intensive care medicine, Intensive Care Med, 22, 707, 10.1007/BF01709751